Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and biomarker predictors of side effects from tamoxifen.

Breast cancer research and treatment - 1 Apr 2012

Lorizio Wendy, Wu Alan H B, Beattie Mary S, Rugo Hope, Tchu Simone, Kerlikowske Karla, Ziv Elad

Abstract excerpt

Tamoxifen decreases breast cancer recurrence, mortality, and breast cancer risk in high-risk women. Despite these proven benefits, tamoxifen use is often limited due to side effects. We identified predictors of tamoxifen-induced side effects based on clinical variables and serum tamoxifen metabolite biomarkers in a cross-sectional study of patients taking tamoxifen. We enrolled 241 women and collected data on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Logistic Models

Share to Maintenance Chemotherapy

Share to Multivariate Analysis

Share to Neoplasm Recurrence, Local

Share to Tamoxifen

Source

Open in PubMed Open full text

Identifiers

PMID: 22207277
DOI: 10.1007/s10549-011-1893-4
PMCID: PMC3335925

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and biomarker predictors of side effects from tamoxifen.PMID 22207277Read ↗

CYP2D6 genotype and endoxifen plasma concentration do not predict hot flash severity during tamoxifen therapy.Semantic proximity Read ↗

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.Semantic proximity Read ↗

Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifenSemantic proximity Read ↗

A Genome-Wide Association Study of Endoxifen Serum Concentrations and Adjuvant Tamoxifen Efficacy in Early-Stage Breast Cancer Patients.Semantic proximity Read ↗

Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer.Semantic proximity Read ↗

Association Analysis among Tamoxifen Metabolites and Genetic Polymorphisms in Hormone-Dependent Chilean Breast Cancer Patients: A Preliminary StudySemantic proximity Read ↗

CYP2D6 and Endoxifen in Tamoxifen Therapy: A Tribute to David A. Flockhart.Semantic proximity Read ↗

Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients.Semantic proximity Read ↗

CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy.Semantic proximity Read ↗

Endoxifen levels and metabolic phenotype-associated factors in Mexican Mestizo patients under tamoxifen treatment.Semantic proximity Read ↗

Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites.Semantic proximity Read ↗

CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.